Authors

Latest:

The Microbiome and Colon Cancer: Dietary Influence on Incidence, Morbidity, and Mortality

One of the prime risk factors for CRC is the consumption of a high-risk, Western-style diet high in processed foods, refined grains, red meat, and sugar.

Anita Kumar, MD

Latest:

Dr. Kumar on Treatment Considerations with BTK Inhibitors in MCL

Anita Kumar, MD, discusses considerations for the use of second-line BTK inhibitors in patients with mantle cell lymphoma who progress on BTK inhibitors.

Jennifer Woyach, MD, Ohio State University

Latest:

Emerging Agents for R/R CLL

Experts discuss emerging agents for the treatment of relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).

Rebecca A. Shatsky, MD

Latest:

BRCA Testing in Early-Stage and Metastatic Breast Cancer

Panelists discuss their approach to BRCA testing in early-stage versus metastatic breast cancer patients, highlighting the 2024 American Society of Clinical Oncology (ASCO) guidelines for germline testing and exploring which patients are not tested for BRCA, as well as how they differentiate between germline and somatic testing approaches.

Noelle Loconte, MD, FASCO

Latest:

Carbone Partner Perspectives: Alcohol: The Carcinogen We’re Not Talking About

Despite alarming figures and trends, public awareness of alcohol as a carcinogen remains low.

Hans Wildiers, MD

Latest:

Dr. Wildiers on the Final Results of the AIPAC Trial in HR+/HER2- Metastatic Breast Cancer

Hans Wildiers, MD, medical oncologist, Department of Medical Oncology, full professor, Faculty of Medicine, member, Laboratory of Experimental Oncology, University Hospital Leuven, Leuven, Belgium, discusses the final results of the phase 2b AIPAC trial (NCT02614833) in hormone receptor (HR)–positive, HER2-negative metastatic breast cancer.

Yoomi Lee, MD

Latest:

Dr. Lee on Selecting a Treatment Approach for Neuroendocrine Tumors

Yoomi Lee, MD, discusses her process for selecting a treatment approach for patients with neuroendocrine tumors.

US Oncology

Latest:

McKesson’s Practice Insights Designated as a 2024 Qualified Clinical Data Registry by Centers for Medicare & Medicaid Services

McKesson has received approval from the CMS to participate in the Merit-based Incentive Payment System as a Qualified Clinical Data Registry.

Cancer Treatment Centers of America

Latest:

Cancer Treatment Centers of America Grows Medical Oncologist Roster Across Hospitals

Medical oncologists Dr. Ajaz Khan, Dr. Ryan Engel, and Dr. Nitika Sharma are the latest board-certified, fellowship-trained physicians who have chosen to practice medicine at Cancer Treatment Centers of America®.

Mohamad Ezzeddine Allaf, MD

Latest:

Dr. Allaf on Evaluating the PROSPER-RCC Trial Results in RCC

Mohamad Ezzeddine Allaf, MD, discusses several key considerations when interpreting and extrapolating initial results from the phase 3 PROSPER-RCC trial in renal cell carcinoma.

Dan Lodder, MBA

Latest:

The Future of Reimbursement: How AI Can Revolutionize Oncology Practices

By retrospectively analyzing health care financial data and using the intelligence generated to guide future claims to a more successful outcome, machine learning platforms may reduce the need for repeated insurance submissions and appeals and can improve the practice’s clean claim rate.

UC Davis Comprehensive Cancer Center

Latest:

UC Davis Researchers Help Decode the Cause of Aggressive Breast Cancer in Women of Color

Findings point to a biomarker that may give a “head start” to triple-negative breast cancer in Black women.

Apar Ganti, MD, University of Nebraska Medical Center

Latest:

Recent Advances in Small-Cell Lung Cancer

Lydia Mills, MSW, LCSW, LICSW

Latest:

McKesson's Patient-Reported Outcomes Measure Will Track Improvements in Health-Related Social Needs

The use of patient-reported outcome measures—the gold standard in quality measurement—is crucial to building a patient-centered, value-based care system.

Laurence Albigès, MD, PhD

Latest:

Dr Albigès on the Predictive and Prognostic Utility of KIM-1 in High-Risk RCC

Laurence Albigès, MD, PhD, discusses the potential predictive and prognostic value of circulating KIM-1 in patients with renal cell carcinoma.

Oana Catalina Rosca, MD

Latest:

Dr Rosca on Key Challenges in Genetic Testing for Lung Cancer

Oana Catalina Rosca, MD, discusses key challenges in genetic testing for lung cancer.

Cindy Neunert, MD

Latest:

Future Directions in the Management of Immune Thrombocytopenia

Expert panelists reflect on the advent of newer therapies in immune thrombocytopenia and look toward future evolutions in care.

Neil Desai, MD

Latest:

Dr Desai on the Benefits and Limitations of Bladder Preservation With Chemoradiation in MIBC

Neil Desai, MD, discusses the potential benefits and limitations of utilizing chemoradiation or triple modality therapy for bladder preservation in the upfront management of patients with locally advanced, nonmetastatic muscle-invasive bladder cancer.

Mitchell E. Horwitz, MD

Latest:

Quality of Life and Patient Reported Outcomes (PRO) in Chronic GVHD

The expert doctors discuss the impact of chronic GVHD on long-term survivors' quality of life (QoL). The panel explores the significance of patient-reported outcomes (PROs), challenges in their implementation, and the evolving role of PROs in assessing and improving QoL in chronic GVHD patients.

VCU Massey Cancer Center

Latest:

Long-Term Survivors of Childhood Cancer at Higher Risk of Death Following Heart Issues; Threshold for Treating Risk Factors Should Be Lower

Survivors of childhood cancer are at a significantly higher risk of death following a major cardiovascular event than the general public.